Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 8/20 | 0.39 |
| ▸ | INSR | P06213 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274410 | 0.87 | ITK (0.39) | ITKINSRCNR2JAK2JAK1 | |
| SCHEMBL6415126 | 0.87 | ITK (0.38) | ITKINSRCNR2F2RBACE1 | |
| SCHEMBL6419231 | 0.86 | BACE1 (0.37) | ITKINSRCNR2F2RBACE1 | |
| SCHEMBL14708857 | 0.84 | ITK (0.46) | ITKINSRCNR2F2RBACE1 | |
| SCHEMBL14708876 | 0.84 | ITK (0.39) | ITKINSRCNR2F2RBACE1 | |
| SCHEMBL21310889 | 0.83 | BACE1 (0.39) | ITKINSRCNR2F2RBACE1 | |
| SCHEMBL6277070 | 0.83 | ALDH1A1 (0.38) | ITKINSRCNR2F2RBACE1 | |
| SCHEMBL14708819 | 0.83 | ITK (0.55) | ITKINSR | |
| SCHEMBL14698995 | 0.82 | ITK (0.49) | ITKINSRJAK2JAK1TYK2 | |
| SCHEMBL14697486 | 0.81 | ITK (0.49) | ITKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | ITK 2/4885INSR 910/4885CNR2 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.